Novo Nordisk A/s Class B · OMXCOP:NOVO_B
Novo Nordisk A/s Class B — Investor Day (September 2026)
20 slides from Novo Nordisk A/s Class B's investor day presentation, Sep 21, 2026
Slide 1: Cardiovascular & liver diseases
Cardiovascular & liver diseases Hong Chow CMD26 EVP, Product & Portfolio Strategy Martin Holst Lange CSO, EVP, Research & Development Capital Markets Day 21 September
Slide 2: Forward-looking statements
2 Cardiovascular & liver diseases Forward-looking statements Novo Nordisk’s statutory Annual Report 2025, Form 20-F, any quarterly financial reports, the materials displayed and other information provided (orally or in writing) at this Capital Markes Day as well as written information released, show
Slide 3: The cardiometabolic franchise provides a natural platform for expansion into cardiovascular and liver disease
3 Cardiovascular & liver diseases The cardiometabolic franchise provides a natural platform for expansion into cardiovascular and liver disease Treatment decisions increasingly reflecting the link Strengthen and MASH management increasingly aligns across between metabolic health and cardiovascular r
Slide 4: Novo's strategic focus on cardiovascular disease addresses a large and growing unmet need
4 Cardiovascular & liver diseases Novo’s strategic focus on cardiovascular disease addresses a large and growing unmet need The prevalence of cardiovascular disease is projected to nearly The ASCVD and heart failure market is already large and expected double by 2050, reaching more than 1.1 billion
Slide 5: Residual cardiovascular risk continues to drive unmet need, with inflammation recognised as an important contributor
5 Cardiovascular & liver diseases Residual cardiovascular risk continues to drive unmet need, with inflammation recognised as an important contributor People living with diabetes and obesity have a Inflammation is recognised as a high-value target across ASCVD, 2-3x higher risk of ASCVD and heart fa
Slide 6: ATTR-CM remains profoundly undertreated and poorly served, creating a blockbuster opportunity for Coramitug's novel MoA
6 Cardiovascular & liver diseases ATTR-CM remains profoundly undertreated and poorly served, creating a blockbuster opportunity for Coramitug’s novel MoA Up to 150,000 in the US suffer from ATTR- Patients face poor outcomes and limited ATTR-CM represents a large and CM with only ~14k treated today t
Slide 7: Novo is well-positioned to address the high unmet need in cardiovascular disease
7 Cardiovascular & liver diseases Novo is well-positioned to address the high unmet need in cardiovascular disease Combining patient scale, trial expertise Novo is building a broad and differentiated early and and market access to address CVD late-stage pipeline within CVD Novo currently treats >45
Slide 8: MASH represents a large, rapidly expanding opportunity with a high unmet need
8 Cardiovascular & liver diseases MASH represents a large, rapidly expanding opportunity with a high unmet need, particularly in the advanced stages of disease The global burden of MASH is prominent with high unmet need, The hepatology market is expected to grow with a +17% CAGR in particularly in t
Slide 9: Alcohol-related liver disease is an emerging frontier in liver fibrosis
9 Cardiovascular & liver diseases Alcohol-related liver disease is an emerging frontier in liver fibrosis, driven by severe disease burden and no approved therapies 1.9 million in the US suffer from ALD, yet share of diagnosed ALD is the leading cause of liver transplants patients remain low Waitlis
Slide 10: Novo is well-positioned to address the high unmet need in liver disease
10 Cardiovascular & liver diseases Novo is well-positioned to address the high unmet need in liver disease Combining patient scale, trial expertise and Building a late-stage MASH portfolio that targets a broad market access to address liver disease spectrum of unmet needs in Steatotic Liver Disease
Slide 11: Novo continues strategic partnerships to further advance progress in enhancing MASH diagnosis
11 Cardiovascular & liver diseases Novo continues strategic partnerships to further advance progress in enhancing MASH diagnosis Building on the Echosens collaboration, Novo is partnering with Siemens Healthineers and Roche Diagnostics Available in +140 countries, millions of liver exams performed s
Slide 12: ZEUS generated important learnings for advancing inflammation-targeted therapies, despite not reducing MACE
12 Cardiovascular & liver diseases ZEUS generated important learnings for advancing inflammation- targeted therapies, despite not reducing MACE ZEUS studied ziltivekimab in 6,376 Ziltivekimab demonstrated target engagement and IL-6 pathway inhibition, reflected in participants with ASCVD and CKD exp
Slide 13: NLRP3 offers a differentiated upstream approach with the potential to unlock greater impact on residual inflammatory risk
13 Cardiovascular & liver diseases NLRP3 offers a differentiated upstream approach with the potential to unlock greater impact on residual inflammatory risk NLRP3 inhibition targets inflammation upstream of IL-6, offering a differentiated approach Novo is developing multiple oral small- to inflammat
Slide 14: Combining oral GLP-1 and PCSK9i could accelerate entry into traditional CV risk factors
14 Cardiovascular & liver diseases Combining oral GLP-1 and PCSK9i could accelerate entry into traditional CV risk factors through proven mechanisms Oral PCSK9i demonstrated superior LDL Oral PCSK9i/GLP-1 holds potential to bring First human dose will be initiated in 2027, lowering versus placebo in
Slide 15: In heart failure, coramitug offers a differentiated mechanism of action currently in phase 3
15 Cardiovascular & liver diseases In heart failure, coramitug offers a differentiated mechanism of action currently in phase 3 development for ATTR-CM Coramitug is an antibody designed to deplete amyloid deposits and thereby reverse ATTR-CM Today Current standard of care Coramitug Amyloid deposits
Slide 16: Coramitug's mechanism of action has the potential to address important unmet needs in heart failure
16 Cardiovascular & liver diseases Coramitug’s mechanism of action has the potential to address important unmet needs in heart failure In the dose-finding phase 2 study, coramitug demonstrated solid The phase 3 CleopATTRa study with coramitug is ongoing biological and cardiac activity with disease r
Slide 17: UBT251 offers next-generation incretin therapy in MASH with differentiated liver benefits
17 Cardiovascular & liver diseases UBT251 offers next-generation incretin therapy in MASH with differentiated liver benefits and high weight loss potential GLP-1, GIP and glucagon tri-agonism targets UBT251 phase 3 in MASH (F2-F3) key metabolic drivers of MASH Key metabolic drivers of MASH UBT251 tr
Slide 18: Efruxifermin brings first and best-in-class potential antifibrotic efficacy
18 Cardiovascular & liver diseases Efruxifermin brings first and best-in-class potential antifibrotic efficacy, with ability to reverse cirrhosis in advanced disease (F4c) Efruxifermin is currently the only treatment to show significant Efruxifermin will be positioned for MASH F4c with fibrosis regr
Slide 19: Novo's cardiovascular and liver disease pipeline supports durable long-term growth
19 Cardiovascular & liver diseases Novo’s cardiovascular and liver disease pipeline supports durable long-term growth Novo cardiovascular and liver disease pipeline 2026 2027 2028 2029 Ziltivekimab (AMI) Phase 3 Coramitug Phase 3 CDR132L Phase 2 NLRP3i Phase 1 (NN6022 + NN6708) CNP Phase 1 Oral IL-6
Slide 20: Cardiovascular and liver disease represent a large and growing opportunity
20 Cardiovascular & liver diseases 1 2 3 Cardiovascular and liver disease represent a Novo is uniquely positioned to address these A broad early- and late-stage pipeline targets large and growing opportunity diseases through patient overlap and multiple disease drivers, several of which established